Evommune Inc. (EVMN) vs Protalix BioTherapeutics, Inc. (PLX)
- Evommune Inc. EVMN 5.17 −12.82%
- Protalix BioTherapeutics, Inc. PLX 2.62 −2.96%
Evommune Inc. and Protalix BioTherapeutics, Inc. are both Biotechnology companies. Evommune Inc. and Protalix BioTherapeutics, Inc. are of similar size ($217.5M and $215.2M). Evommune Inc. has negative trailing earnings, so its P/E is not meaningful; Protalix BioTherapeutics, Inc. trades at 11.4×. Protalix BioTherapeutics, Inc. has the higher net margin (23.5% vs 0.00%) and the higher return on invested capital (48.5% vs −82.5%). Across the 13 metrics below, Protalix BioTherapeutics, Inc. leads on 9 and Evommune Inc. on 4.
Valuation
Profitability
| Metric | EVMN | PLX | Biotechnology median |
|---|---|---|---|
| Gross margin | — | 69.20% | 65.16% |
| Operating margin | 0.00% | 28.89% | 0.00% |
| Net margin | 0.00% | 23.50% | 0.00% |
| Free cash flow margin | 0.00% | 9.51% | 0.00% |
| Return on equity | (141.99%) | 31.23% | (56.36%) |
| Return on assets | (62.71%) | 20.07% | (48.04%) |
| Return on invested capital | (82.46%) | 48.48% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack